Personalised medicine is an approach that entails the tailoring of treatment on the basis of the exploration of patient biomarkers identified through genetic testing. This approach holds significant potential for all stakeholders: patients, industry and public healthcare providers. For patients, it means more effective and safer treatments. For industry, it means more efficient drug development. Furthermore, personalised medicine offers the potential for long-term economic sustainability for public healthcare providers. Consequently, personalised medicine has been identified as a key priority for the EU.